Skip to main content

One Wales Medicines interim decisions

Infliximab for the treatment of ICI induced enterocolitis (OW21)

Issue date: 13/09/2024

Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22)

Issue date: 13/09/2024

Nivolumab for oesophageal and gastric cancer (OW28)

Issue date: 11/07/2024

Rituximab for myasthenia gravis (OW12)

Last review date: July 2024

Denosumab (Prolia®) for osteoporosis in men (OW07)

Last review date: December 2022

Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25)

Last review date: May 2024

Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24)

Last review date: May 2024

Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23)

Last review date: May 2024

Dabrafenib and trametinib for anaplastic thyroid cancer (OW27)

Issue date: April 2024

Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20)

Last review date: April 2024

Bevacizumab for ovarian cancer (OW01)

Last review date: February 2024

Bendamustine and rituximab for mantle cell lymphoma (OW09)

Last review date: February 2024

Bendamustine and rituximab for indolent lymphomas (OW08)

Last review date: February 2024

Rituximab for interstitial lung disease (OW13)

Last review date: February 2024

Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19)

Last review date: November 2023

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04)

Last review date: November 2023

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06)

Last review date: September 2023

Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16)

Last review date: September 2023

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15)

Last review date: August 2023

Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26)

Issue date: 03/08/2023

Follow AWTTC: